Business Wire

Samsara Eco and NILIT Team up to Build World-First Nylon 6,6 Recycling Facility

26.8.2024 22:00:00 EEST | Business Wire | Press release

Share

Samsara Eco, the enviro-tech innovator and NILIT, the world’s leader in the production of nylon 6,6 for apparel, have announced plans to explore investment and construction of a nylon 6,6 textile-to-textile recycled polymer production site in South East Asia to help close the loop on nylon 6,6.

Roughly 4 million tonnes of nylon 6,6 is created every year, it is one of the most widely used fibers in the performance apparel and fashion industries. However, it is notoriously difficult to recycle and when blended with other fibres like spandex, it increases the challenge. Together, Samsara Eco and NILIT are seeking to address this issue head-on.

Aiming to be operational by late 2026, the anticipated facility will be uniquely capable of recycling textile waste, producing high-quality recycled nylon 6,6 polymers, for textile brands and manufacturers to seamlessly use in their existing supply chains to create new textile fabrics, infinitely.

“Our vision is to deliver climate repair through infinite recycling. One of the ways we’re achieving this is by creating the first circular pathway for nylon 6,6. Discarded clothing made from nylon 6,6 such as activewear, and even products like car interiors, typically end up in landfill or are incinerated at the end of life, which has dire consequences for our planet,” said Paul Riley, CEO and Founder of Samsara Eco.

Sarah Cook, Chief Commercial and Operations Officer of Samsara Eco also commented on the agreement: “By working with NILIT, we can reverse this trend and give apparel a new life. The MoU agreement is an important step to help brands and the world advance nylon 6,6 circularity and reduce plastic waste. We’re proud to be exploring a pilot recycling facility with NILIT, setting a precedent of what’s possible for future partners globally.”

“NILIT’s partnership with Samsara Eco is a critical step in our multi-pronged strategy to provide the apparel market with premium nylon 6,6 products that have lower environmental impact,” explained Ilan Melamed, NILIT General Manager.“Implementing textile-to-textile recycling solutions will substantially decrease global carbon emissions and reduce the 92 million tonnes of textile waste added to landfills annually. Together, NILIT and Samsara Eco have the potential to produce infinitely recycled nylon 6,6 that delivers outstanding fabric quality and performance while benefitting the planet.”

EosEco™ is the world's first technology to infinitely recycle nylon 6,6 by combining biophysics, chemistry, biology and computer science (such as AI) to create a family of plastic-eating enzymes. The enzymes break down plastic waste, including textiles made from nylon 6,6 into raw materials, which are then seamlessly integrated into existing manufacturing processes to create a truly closed loop. EosEco™ can recycle a breadth of feedstock inputs, including coloured and blended textiles like nylon 6,6 with spandex. EosEco™, together with NILIT’s unique polymerization, spinning and technology will be able to create premium recycled Nylon 6, 6 yarn for global consumption.

About NILIT

Celebrating 50 years of excellence, NILIT offers the broadest collection of premium sustainable Nylon 6,6 yarns designed to empower the apparel industry’s shift to a more sustainable position. Operating internationally, NILIT is the global leader in Nylon 6,6 yarns for apparel, dedicated to creating innovative and sustainable solutions that advance the textile industry.

NILIT will add Samsara Eco’s EosEco™ produced yarn to its innovative SENSIL® preferred portfolio of products which is manufactured according to NILIT’s Total Product Sustainability criteria. These responsible yarns give designers the beautiful, environmentally considerate performance fabrics they need to create apparel collections that respond to consumer demands.

About Samsara Eco

Samsara Eco is using advanced, enzymatic recycling to end plastic pollution. With breakthrough science, Samsara Eco has developed a new way to break plastic down to its core molecules, which can then be used to recreate brand-new plastic, again and again. Its patented technology, EosEco™ is a first-of-its-kind process that is genuinely better for the planet.

Samsara Eco’s community is united by the shared mission to divert plastic from our landfills and oceans, and eliminate the need to create plastic from fossil fuels, (whether it’s for the bottles we drink from or the clothes we wear) for a cleaner and more sustainable future.

In partnership with the Australian National University (ANU), Samsara Eco launched in 2020 with the backing of Main Sequence and Woolworths Group’s W23. It has raised more than AUD $160M in funding from local and global investors including Breakthrough Victoria, DCVC, Hitachi, lululemon, Temasek, Wildcard Ventures, Wollemi Capital and more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820332060/en/

Contacts

Michelle Lea
michellel@nilit.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release

Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release

Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release

Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye